Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$200M · US$20.13 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead) Buyers: Braidwell LP; Cormorant Asset Management; Driehaus Capital Management; Invus; Janus Henderson Investors; MPM BioImpact; OrbiMed; Paradigm BioCapital Advisors; Perceptive Advisors; RA Capital Management; Sofinnova Investments, Inc. Use of proceeds: Potential US launch of sevasemten in Becker, Phase 3 trials of sevasemten and EDG-7500, other R&D, working capital and general corporate purposes | Apr 2, 2025 |